OneSpan Inc vs BIO-TECHNE Corp — how do they compare? OneSpan Inc trades at $17.96 (market cap $652.28M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 17.4× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and BIO-TECHNE Corp for 63 Days on average.
| OSPN | TECH | |
|---|---|---|
Market Cap | $652.28M | $11.37B |
Volume | 590,167 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $18.42 | $72.61 |
52-Week Low | $10.15 | $43.31 |
Typical Hold Time | 18 Days | 63 Days |
Enterprise Value | $621.36M | $11.40B |
Dividend Yield | 2.94% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 27.76% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and a new product launch, DigipassONE, aimed at authentication modernization.
The outlook remains positive given consistent earnings beats and a strong analyst buy consensus, though risks include negative net cash flow trends and competitive pressures in the technology sector. Revenue growth is modest, but high margins and a reasonable P/E of 10 support valuation. The stock presents a value opportunity with controlled risk.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →